4 hours Arcus Biosciences (NYSE:RCUS) Now Covered by Analysts at Wells Fargo & Company MarketBeat
Wells Fargo & Company assumed coverage on shares of Arcus Biosciences in a report on Tuesday. They issued an “overweight” rating and a $29.00 price objective for the company.